Literature DB >> 30626758

Metabolic and microstructural alterations in the SLE brain correlate with cognitive impairment.

Meggan Mackay1, An Vo2, Chris C Tang2, Michael Small2, Erik W Anderson1, Elisabeth J Ploran3, Justin Storbeck4, Brittany Bascetta4, Simran Kang4, Cynthia Aranow1, Carl Sartori1, Philip Watson5, Bruce T Volpe1, Betty Diamond1, David Eidelberg2.   

Abstract

To address challenges in the diagnosis of cognitive dysfunction (CD) related to systemic lupus erythematosus-associated (SLE-associated) autoimmune mechanisms rather than confounding factors, we employed an integrated approach, using resting-state functional (FDG-PET) and structural (diffusion tensor imaging [DTI]) neuroimaging techniques and cognitive testing, in adult SLE patients with quiescent disease and no history of neuropsychiatric illness. We identified resting hypermetabolism in the sensorimotor cortex, occipital lobe, and temporal lobe of SLE subjects, in addition to validation of previously published resting hypermetabolism in the hippocampus, orbitofrontal cortex, and putamen/GP/thalamus. Regional hypermetabolism demonstrated abnormal interregional metabolic correlations, associated with impaired cognitive performance, and was stable over 15 months. DTI analyses demonstrated 4 clusters of decreased microstructural integrity in white matter tracts adjacent to hypermetabolic regions and significantly diminished connecting tracts in SLE subjects. Decreased microstructural integrity in the parahippocampal gyrus correlated with impaired spatial memory and increased serum titers of DNRAb, a neurotoxic autoantibody associated with neuropsychiatric lupus. These findings of regional hypermetabolism, associated with decreased microstructural integrity and poor cognitive performance and not associated with disease duration, disease activity, medications, or comorbid disease, suggest that this is a reproducible, stable marker for SLE-associated CD that may be may be used for early disease detection and to discriminate between groups, evaluate response to treatment strategies, or assess disease progression.

Entities:  

Keywords:  Autoimmune diseases; Autoimmunity; Neuroimaging; Neuroscience

Year:  2019        PMID: 30626758      PMCID: PMC6485360          DOI: 10.1172/jci.insight.124002

Source DB:  PubMed          Journal:  JCI Insight        ISSN: 2379-3708


  68 in total

1.  Factor analysis of computerized and traditional tests used in mild brain injury research.

Authors:  J Bleiberg; R L Kane; D L Reeves; W S Garmoe; E Halpern
Journal:  Clin Neuropsychol       Date:  2000-08       Impact factor: 3.535

2.  Improved optimization for the robust and accurate linear registration and motion correction of brain images.

Authors:  Mark Jenkinson; Peter Bannister; Michael Brady; Stephen Smith
Journal:  Neuroimage       Date:  2002-10       Impact factor: 6.556

3.  An inventory for measuring depression.

Authors:  A T BECK; C H WARD; M MENDELSON; J MOCK; J ERBAUGH
Journal:  Arch Gen Psychiatry       Date:  1961-06

4.  Decreased regional cerebral metabolic rate for glucose in systemic lupus erythematosus patients with psychiatric symptoms.

Authors:  N Komatsu; K Kodama; N Yamanouchi; S Okada; S Noda; Y Nawata; K Takabayashi; I Iwamoto; Y Saito; Y Uchida; H Ito; K Yoshikawa; T Sato
Journal:  Eur Neurol       Date:  1999-07       Impact factor: 1.710

5.  A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus.

Authors:  L A DeGiorgio; K N Konstantinov; S C Lee; J A Hardin; B T Volpe; B Diamond
Journal:  Nat Med       Date:  2001-11       Impact factor: 53.440

6.  Outcome of neuropsychiatric systemic lupus erythematosus within a defined Swedish population: increased morbidity but low mortality.

Authors:  A Jönsen; A A Bengtsson; O Nived; B Ryberg; G Sturfelt
Journal:  Rheumatology (Oxford)       Date:  2002-11       Impact factor: 7.580

7.  Diagnosis and monitoring of central nervous system involvement in systemic lupus erythematosus: value of F-18 fluorodeoxyglucose PET.

Authors:  S M Weiner; A Otte; M Schumacher; R Klein; J Gutfleisch; I Brink; P Otto; E U Nitzsche; E Moser; H H Peter
Journal:  Ann Rheum Dis       Date:  2000-05       Impact factor: 19.103

8.  The prevalence of neuropsychiatric syndromes in systemic lupus erythematosus.

Authors:  H Ainiala; J Loukkola; J Peltola; M Korpela; A Hietaharju
Journal:  Neurology       Date:  2001-08-14       Impact factor: 9.910

9.  Immunosuppression prevents neuronal atrophy in lupus-prone mice: evidence for brain damage induced by autoimmune disease?

Authors:  B Sakic; B Kolb; I Q Whishaw; G Gorny; H Szechtman; J A Denburg
Journal:  J Neuroimmunol       Date:  2000-11-01       Impact factor: 3.478

10.  Neuropsychiatric syndromes in lupus: prevalence using standardized definitions.

Authors:  R L Brey; S L Holliday; A R Saklad; M G Navarrete; D Hermosillo-Romo; C L Stallworth; C R Valdez; A Escalante; I del Rincón; G Gronseth; C B Rhine; P Padilla; D McGlasson
Journal:  Neurology       Date:  2002-04-23       Impact factor: 9.910

View more
  14 in total

1.  GALECTIN-8 Is a Neuroprotective Factor in the Brain that Can Be Neutralized by Human Autoantibodies.

Authors:  Evelyn Pardo; Francisca Barake; Juan A Godoy; Claudia Oyanadel; Sofía Espinoza; Claudia Metz; Claudio Retamal; Loreto Massardo; Cheril Tapia-Rojas; Nibaldo C Inestrosa; Andrea Soza; Alfonso González
Journal:  Mol Neurobiol       Date:  2019-05-22       Impact factor: 5.590

Review 2.  Cognitive Dysfunction in Systemic Lupus Erythematosus: A Case for Initiating Trials.

Authors:  Nina Kello; Erik Anderson; Betty Diamond
Journal:  Arthritis Rheumatol       Date:  2019-08-07       Impact factor: 10.995

3.  TWEAKing the Hippocampus: The Effects of TWEAK on the Genomic Fabric of the Hippocampus in a Neuropsychiatric Lupus Mouse Model.

Authors:  Dumitru A Iacobas; Jing Wen; Sanda Iacobas; Chaim Putterman; Noa Schwartz
Journal:  Genes (Basel)       Date:  2021-07-29       Impact factor: 4.096

Review 4.  Pathophysiology of cognitive dysfunction and the role of combined brain/heart magnetic resonance imaging (Review).

Authors:  George Markousis-Mavrogenis; Flora Bacopoulou; Genovefa Kolovou; Maria-Roser Pons; Aikaterini Giannakopoulou; Antigoni Papavasiliou; George D Kitas; George P Chrousos; Sophie I Mavrogeni
Journal:  Exp Ther Med       Date:  2022-07-14       Impact factor: 2.751

Review 5.  Structure, Function, and Pharmacology of Glutamate Receptor Ion Channels.

Authors:  Kasper B Hansen; Lonnie P Wollmuth; Derek Bowie; Hiro Furukawa; Frank S Menniti; Alexander I Sobolevsky; Geoffrey T Swanson; Sharon A Swanger; Ingo H Greger; Terunaga Nakagawa; Chris J McBain; Vasanthi Jayaraman; Chian-Ming Low; Mark L Dell'Acqua; Jeffrey S Diamond; Chad R Camp; Riley E Perszyk; Hongjie Yuan; Stephen F Traynelis
Journal:  Pharmacol Rev       Date:  2021-10       Impact factor: 18.923

Review 6.  The diverse and complex modes of action of anti-NMDA receptor autoantibodies.

Authors:  Lonnie P Wollmuth; Kelvin Chan; Laurent Groc
Journal:  Neuropharmacology       Date:  2021-05-31       Impact factor: 5.250

7.  Assessing cognitive impairment in SLE: examining relationships between resting glucose metabolism and anti-NMDAR antibodies with navigational performance.

Authors:  Elisabeth Ploran; Chris Tang; Meggan Mackay; Michael Small; Erik Anderson; Justin Storbeck; Brittany Bascetta; Simran Kang; Cynthia Aranow; Carl Sartori; Philip Watson; Bruce Volpe; Betty Diamond; David Eidelberg
Journal:  Lupus Sci Med       Date:  2019-07-11

Review 8.  Advanced neuroimaging in neuropsychiatric systemic lupus erythematosus.

Authors:  Meggan Mackay; Chris C Tang; An Vo
Journal:  Curr Opin Neurol       Date:  2020-06       Impact factor: 5.710

Review 9.  Advances in the diagnosis, pathogenesis and treatment of neuropsychiatric systemic lupus erythematosus.

Authors:  Erica Moore; Michelle W Huang; Chaim Putterman
Journal:  Curr Opin Rheumatol       Date:  2020-03       Impact factor: 4.941

Review 10.  Cognitive dysfunction in autoimmune rheumatic diseases.

Authors:  Csaba Oláh; Noa Schwartz; Christopher Denton; Zsófia Kardos; Chaim Putterman; Zoltán Szekanecz
Journal:  Arthritis Res Ther       Date:  2020-04-15       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.